Linsitinib is an IGF‐1R and insulin receptor inhibitor (Mulvihill et al, 2009) currently under investigation for various types of cancer due to its ability to prevent tumor cell proliferation and induce tumor cell apoptosis (Fassnacht et al, 2015). Here, IGF1R is linked to neoplasm.